Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (698kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-534982
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.53498
Diese Publikation ist Teil des DEAL-Vertrags mit Springer.
Zusammenfassung
Recently, molecular tumour boards (MTBs) have been integrated into the clinical routine. Since their benefit remains debated, we assessed MTB outcomes in the Comprehensive Cancer Center Ostbayern (CCCO) from 2019 to 2021. Methods and results In total, 251 patients were included. Targeted sequencing was performed with PCR MSI-evaluation and immunohistochemistry for PD-L1, Her2, and mismatch ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags